3 terminated, 1 completed. 2 Phase 3, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
| Not applicable | 1 | Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Tecemotide: new trials by email Literature Review of Tecemotide trials Research Report on Tecemotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer Tecemotide, Placebo, Cyclophosphamide (CPA) - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | EMD Serono | 35 | 2014-03-01 | 2017-08-23 |
| Common Safety Follow-up Trial of Tecemotide (L-BLP25) Tecemotide, No intervention - Non-Small Cell Lung Cancer, Multiple Myeloma | Not applicable | Terminated | Merck KGaA, Darmstadt, Germany | 27 | 2012-01-01 | 2016-10-06 |
| BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery bevacizumab, Tecemotide, carboplatin - Lung Cancer | Phase 2 | Completed | ECOG-ACRIN Cancer Research Group | 70 | 2011-01-17 | 2023-07-07 |
| Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population Tecemotide, Single low dose cyclophosphamide, Placebo - Non-Small Cell Lung Cancer | Phase 3 | Terminated | Merck KGaA, Darmstadt, Germany | 285 | 2009-12-01 | 2016-10-26 |
Carcinoma, Non-Small-Cell Lung (4) · Adenocarcinoma of Lung (1) · Lung Neoplasms (1) · Multiple Myeloma (1)
Merck KGaA, Darmstadt, Germany (2) · ECOG-ACRIN Cancer Research Group (1) · EMD Serono (1)
Germany (2) · United States (2) · China (1) · Hong Kong (1) · Singapore (1) · South Korea (1) · Taiwan (1)
Jyoti D. Patel (1)
U10CA180794 (1)